Merck & Co. Stock

$79.16

0.08% yesterday

NYSE, Jun 30, 10:10 pm CET

ISIN

US58933Y1055

Symbol

MRK

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Merck & Co. Stock price

$79.16

+5.42 7.36% 5Y

NYSE, Closing price Mon, Jun 30 2025

+0.06 0.08%

ISIN

US58933Y1055

Symbol

MRK

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$198.6b

Enterprise Value

$224.2b

Net debt

$25.6b

Cash

$9.2b

Shares outstanding

2.5b

Valuation (TTM | estimate)

P/E

11.50 | 8.80

P/S

3.11 | 3.02

EV/Sales

3.51 | 3.41

EV/FCF

13.16

P/B

4.12

Dividends

DPS

$3.12

Yield 1Y | 5Y

3.94% | 2.95%

Growth 1Y | 5Y

5.41% | 7.68%

Payout 1Y | 3Y

46.29% | 70.53%

Increased

14 Years

Financials (TTM | estimate)

Revenue

$63.9b | $65.7b

EBITDA

$26.2b | $30.4b

EBIT

$21.6b

Net Income

$17.4b | $22.6b

Free Cash Flow

$17.0b

Growth (TTM | estimate)

Revenue

4.10% | 2.42%

EBITDA

-0.39% | 8.94%

EBIT

-3.79%

Net Income

656.03% | 32.19%

Free Cash Flow

54.34%

Margin (TTM | estimate)

Gross

78.17%

EBITDA

41.06% | 46.24%

EBIT

33.84%

Net

27.27% | 34.43%

Free Cash Flow

26.66%

EPS

$6.88

FCF per Share

$6.77

Short interest

1.59%

Employees

74.00k

Rev per Employee

$870.00k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Merck & Co. Stock Analysis

Unlock Scores for Free

32 Analysts have issued a Merck & Co. forecast:

20x Buy

63%

12x Hold

38%

More details on Analyst Estimates Including Price Targets

32 Analysts have issued a Merck & Co. forecast:

Buy

63%

Hold

38%

Analyst Estimates with Stock Price Targets

Financial data from Merck & Co.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	63,922 63,922	4% 4% 100%
- Direct Costs	13,956 13,956	10% 10% 22%
Gross Profit	49,966 49,966	9% 9% 78%
- Selling and Administrative Expenses	10,779 10,779	4% 4% 17%
- Research and Development Expense	17,557 17,557	34% 34% 27%
EBITDA	26,244 26,244	0% 0% 41%
- Depreciation and Amortization	4,614 4,614	19% 19% 7%
EBIT (Operating Income) EBIT	21,630 21,630	4% 4% 34%
Net Profit	17,434 17,434	656% 656% 27%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Merck & Co. Stock News

Positive

Seeking Alpha

●

one day ago

Merck: Don't Let Today's Bargain Opportunity Pass You By

Merck remains a top Big Pharma brand with strong management, expected sales growth, and high profit margins, helped by the revolutionary Keytruda invention.

Positive

Seeking Alpha

●

3 days ago

Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)

Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant share price pullback, now trading at just 10x adjusted earnings and offering a 4% dividend yield. Despite expensive M&A and some new product launches, non-Keytruda sales remain flat, highlighting th...

Positive

Forbes

●

4 days ago

40% Upside For Merck Stock?

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its pipeline. Earlier this month, we highlighted how Keytruda is a ticking time bomb for Merck stock.

More Merck & Co. News

Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Head office	United States
CEO	Robert Davis
Employees	74,000
Founded	1891
Website	www.merck.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now